<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="379">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123017</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-KR-005</org_study_id>
    <nct_id>NCT02123017</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy</brief_title>
  <official_title>An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with
      escalating doses of lactulose to be used as a preparation for colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy.</measure>
    <time_frame>10-14 hours post last consumption</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Preparation Scale (BBPS). 9 is the maximum score, representing an fully cleansed colon; 0 is the minimal score, representing a colon with no cleaning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Incidence</measure>
    <time_frame>1 day post last consumption</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety determined by the incidence of treatment emergent adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Severity</measure>
    <time_frame>1 day post last consumption</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety determined by the severity of treatment emergent adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of and Preference for Bisacodyl and Lactulose as a Bowel Evacuant</measure>
    <time_frame>1 day post last consumption</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tolerability assessed by a patient questionnaire. Overall tolerability as given by Visual Analog Scale (VAS): 100 represents maximally tolerable; 0 represents minimally tolerable</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Colonoscopy Preparation</condition>
  <arm_group>
    <arm_group_label>90 grams of Crystalline Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>135 grams of Crystalline Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 grams of Crystalline Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 grams of Crystalline Lactulose</intervention_name>
    <description>15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses</description>
    <arm_group_label>90 grams of Crystalline Lactulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>135 grams of Crystalline Lactulose</intervention_name>
    <description>15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses</description>
    <arm_group_label>135 grams of Crystalline Lactulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180 grams of Crystalline Lactulose</intervention_name>
    <description>15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses</description>
    <arm_group_label>180 grams of Crystalline Lactulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring bowel evacuation for colonoscopy.

        Exclusion Criteria:

          -  Patients with galactosemia (galactose-sensitive diet).

          -  Patients known to be hypersensitive to any of the components of lactulose for oral
             solution.

          -  Patients with a known abnormality on screening or a vital sign assessments that, in
             the Investigator's judgment, may pose a significant risk including those pertaining
             to dehydration or electrolyte shifts.

          -  Patients with a history of impaired renal function.

          -  Patients with current or recent history of hypotension, as defined by the
             Investigator.

          -  Patients with a history of long Q-T syndrome.

          -  Patients with a history of a failed bowel preparation.

          -  Patients with severe constipation, defined as those patients taking daily
             prescription or over-the-counter laxatives.

          -  Patients with possible bowel obstruction, gastric retention, bowel perforation, toxic
             colitis, toxic megacolon, ileus or previous colonic surgery (except hemorrhoidectomy
             and polypectomy).

          -  Patients on lactulose therapy or receiving any treatment for chronic constipation.

          -  Be pregnant or nursing.

          -  Patients expected to require electrocautery or argon plasma coagulation.

          -  Patients less than 18 years of age.

          -  Inability to understand the requirements of the study or be unwilling to provide
             written informed consent (as evidenced by signature on an informed consent document
             approved by an Institutional Review Board [IRB]) and agree to abide by the study
             restrictions.

          -  Be otherwise unsuitable for the study, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Krause, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClinSearch, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 27, 2016</lastchanged_date>
  <firstreceived_date>April 23, 2014</firstreceived_date>
  <firstreceived_results_date>December 18, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bowel Evacuation</keyword>
  <keyword>Colonoscopy Preparation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bisacodyl</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>90 Grams Crystalline Lactulose</title>
          <description>15 mg bisacodyl, plus 30 grams crystalline lactulose x 3 doses</description>
        </group>
        <group group_id="P2">
          <title>135 Grams Crystalline Lactulose</title>
          <description>15 mg bisacodyl, plus 45 grams crystalline lactulose x 3 doses</description>
        </group>
        <group group_id="P3">
          <title>180 Grams Crystalline Lactulose</title>
          <description>15 mg bisacodyl, plus 60 grams crystalline lactulose x 3 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients adhered to the one set of study-level eligibility criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>90 Grams of Crystalline Lactulose</title>
          <description>15 mg of bisacodyl and 30 grams crystalline lactulose x 3 doses</description>
        </group>
        <group group_id="B2">
          <title>135 Grams of Crystalline Lactulose</title>
          <description>15 mg of bisacodyl and 45 grams crystalline lactulose x 3 doses</description>
        </group>
        <group group_id="B3">
          <title>180 Grams of Crystalline Lactulose</title>
          <description>15 mg of bisacodyl and 60 grams crystalline lactulose x 3 doses</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="12"/>
                <measurement group_id="B4" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Subject Age at Enrollment</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47.4" spread="6.2"/>
                <measurement group_id="B2" value="57.0" spread="7.4"/>
                <measurement group_id="B3" value="58.1" spread="8.7"/>
                <measurement group_id="B4" value="55.0" spread="8.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy.</title>
        <description>Efficacy assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Preparation Scale (BBPS). 9 is the maximum score, representing an fully cleansed colon; 0 is the minimal score, representing a colon with no cleaning.</description>
        <time_frame>10-14 hours post last consumption</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>90 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 30 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O2">
            <title>135 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 45 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O3">
            <title>180 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 60 grams crystalline lactulose x 3 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy.</title>
            <description>Efficacy assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Preparation Scale (BBPS). 9 is the maximum score, representing an fully cleansed colon; 0 is the minimal score, representing a colon with no cleaning.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.7" spread="2.8"/>
                  <measurement group_id="O2" value="7.4" spread="0.9"/>
                  <measurement group_id="O3" value="7.8" spread="0.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Incidence</title>
        <description>Safety determined by the incidence of treatment emergent adverse events.</description>
        <time_frame>1 day post last consumption</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>90 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 30 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O2">
            <title>135 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 45 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O3">
            <title>180 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 60 grams crystalline lactulose x 3 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Incidence</title>
            <description>Safety determined by the incidence of treatment emergent adverse events.</description>
            <units>% of patients with adverse events</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Severity</title>
        <description>Safety determined by the severity of treatment emergent adverse events.</description>
        <time_frame>1 day post last consumption</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>90 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 30 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O2">
            <title>135 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 45 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O3">
            <title>180 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 60 grams crystalline lactulose x 3 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Severity</title>
            <description>Safety determined by the severity of treatment emergent adverse events.</description>
            <units>Percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of and Preference for Bisacodyl and Lactulose as a Bowel Evacuant</title>
        <description>Tolerability assessed by a patient questionnaire. Overall tolerability as given by Visual Analog Scale (VAS): 100 represents maximally tolerable; 0 represents minimally tolerable</description>
        <time_frame>1 day post last consumption</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>90 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 30 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O2">
            <title>135 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 45 grams crystalline lactulose x 3 doses</description>
          </group>
          <group group_id="O3">
            <title>180 Grams of Crystalline Lactulose</title>
            <description>15 mg of bisacodyl and 60 grams crystalline lactulose x 3 doses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tolerability of and Preference for Bisacodyl and Lactulose as a Bowel Evacuant</title>
            <description>Tolerability assessed by a patient questionnaire. Overall tolerability as given by Visual Analog Scale (VAS): 100 represents maximally tolerable; 0 represents minimally tolerable</description>
            <units>units on a VAS scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65.4" spread="27.6"/>
                  <measurement group_id="O2" value="68.5" spread="19.6"/>
                  <measurement group_id="O3" value="71.3" spread="18.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from the first dose of study drug through the end of the observation period after the colonoscopy (Day 2).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>90 Grams of Crystalline Lactulose</title>
          <description>15 mg of bisacodyl and 30 grams crystalline lactulose x 3 doses</description>
        </group>
        <group group_id="E2">
          <title>135 Grams of Crystalline Lactulose</title>
          <description>15 mg of bisacodyl and 45 grams crystalline lactulose x 3 doses</description>
        </group>
        <group group_id="E3">
          <title>180 Grams of Crystalline Lactulose</title>
          <description>15 mg of bisacodyl and 60 grams crystalline lactulose x 3 doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Rock, PhD</name_or_title>
      <organization>Cumberland Pharmaceuticals, Inc.</organization>
      <phone>615-255-0068</phone>
      <email>arock@cumberlandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
